Hansa Biopharma
46,28 SEK −0,34%HC Andersen Capital on aikaisemmin saanut maksun yhtiöltä Hansa Biopharma DigitalIR/Corporate Visibility -sopimuksesta. Tämä tarkoittaa, että sivulta voi löytyä maksettua materiaalia, jota ei ole päivitetty. Katso vastuuvapauslauseke.
Hansa Biopharma is a Swedish biotech company with the lead product imlifidase, which is an antibody-cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients. The enzyme may be further developed for use in other types of transplantation, in autoimmune diseases, gene therapy and oncology. So far Idefirix (imlifidase) has been conditionally approved in the EU for highly sensitized kidney transplant patients. Currently, Hansa is conducting a pivotal randomized contro trial in kidney transplantation in the United States and is expecting to commence a pivotal study across the U.S. and EU in the rare autoimmune disease anti-GBM during 2022. Additionally, Hansa’s research and development program is advancing the enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology.
Lue lisääAnalyst
Viimeisimmät videot
Pörssikalenteri
Suurimmat omistajatLähde: Millistream Market Data AB
Omistaja | Osuus | Ääniä |
---|---|---|
Redmile Group | 18,3 % | 18,3 % |
Nexttobe | 4,1 % | 4,1 % |
Inderes Premium
Tämä sisältö on vain Inderes Premium -käyttäjille.
Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)
Hansa Biopharma AB: Hansa Biopharma publishes prospectus for admission to trading of shares on Nasdaq Stockholm
Liity Inderesin yhteisöön
Älä jää mistään paitsi – luo käyttäjätunnus ja ota kaikki hyödyt irti Inderesin palvelusta.